Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
Links shared publicly online about this topic.
- 1,291total visits
Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
In many cancers, octreotide acetate (Sandostatin) has been reported to control the diarrhea that can accompany chemotherapy. However, for patients receiving combined chemotherapy and radiation for anal or rectal cancers, the drug proved no better than a placebo in a randomized trial that was published ...
View full resource at physorg.com
Tags: Rectum, Diarrhea, Acromegaly Medication, Cancer, Chemotherapy, Rectal Cancer, Drug, Sandostatin
Most Recently Shared on March 24, 2010 at 9:54 pm By:
Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer http://bit.ly/bfPpSi
Also Shared By:
Octreotide Acetate in Prevention of Chemoradiation-Induced Diarrhea in Anorectal Cancer: Randomized RTOG Trial 0315 -- Zachariah et al., 10.1093/jnci/djq063 -- JNCI Journal of the National Cancer Institute
jnci.oxfordjournals.org — “Octreotide Acetate in Prevention of Chemoradiation-Induced Diarrhea in Anorectal Cancer: Randomized RTOG Trial 0315 -- Zachariah et al., 10.1093/jnci/djq063 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org
Most Recently Shared on April 2, 2010 at 3:57 pm By:
J Nat'l Cancer Inst Oncology and Medical Journal
Octreotide acetate does not help control chemotherapy-induced diarrhea, per randomized trial; JNCI study. http://bit.ly/c3iOXs
Advertisement
PhysOrg Health News
@physorg_health
Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer http://tw.physorg.com/188668258
1 year ago...